SLC5A2 and prediabetes syndrome: Nonetheless, the findings of DAPA-HF may provide insights into the underlying effect of SGLT2 inhibition on β-cell dysfunction in the transition from prediabetes to diabetes, and this class of drugs clearly represents an attractive therapeutic option for diabetes prevention.